The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats
Introduction
There is little doubt that tobacco smoking is a major burden to society from various financial and psycho-social perspectives. A scientific case has been made that nicotine is the primary ingredient responsible for maintaining tobacco smoking and inducing dependence (Stolerman and Jarvis, 1995). Tobacco dependence is viewed as a complex disorder (DSM IV) for which there are several treatments available but many smokers find these treatments ineffective. Pharmacological interventions have been restricted to either nicotinic ligands or compounds formerly used as antidepressants (George and O'Malley, 2004), such as bupropion (Zyban™) for which the precise mechanism of action remains unclear (Warner and Shoaib, 2005).
Recent evidence suggests that the endocannabinoid system may play a prominent role in the dependence-producing actions of nicotine (Cohen et al., 2005b, De Vries and Schoffelmeer, 2005). For example, following chronic nicotine treatment, endocannabinoid levels are increased in the limbic forebrain region of rats (Gonzales et al., 2002). These initial observations were applied to nicotine dependence-related measures by examining the cannabinoid CB1 receptor specific antagonist SR141716, now given the proprietary name rimonabant. Pre-treatment with rimonabant attenuated both nicotine self-administration behaviour and nicotine-evoked dopamine release in the nucleus accumbens (NAc) of rats (Cohen et al., 2002). Rimonabant has also been shown to attenuate relapse induced by re-exposure to cocaine-associated cues or cocaine itself, in rats with a history of cocaine self-administration (De Vries et al., 2005), and to attenuate cue-induced reinstatement of nicotine-seeking behaviour in rats (Cohen et al., 2005b) and nicotine-induced conditioned place preference (Le Foll and Goldberg, 2004). Thus, rimonabant may not target a particular substance but rather the motivational aspects associated with drug-taking and drug-seeking behaviours which also extends to natural reinforcers such as sucrose-seeking behaviour that can be suppressed by rimonabant pre-treatment (De Vries et al., 2005).
Recent trials performed with rimonabant (STRATA-US) in smokers motivated to quit produced abstinence rates of 36.2% at 28 days in the study with the 20 mg dose (odds ratio 2.2) compared to 20.6% with placebo (Anthenelli, 2004). Given the benefits of rimonabant on weight gain, some of its efficacy may be linked to the 75% reduction in post-cessation weight gain amongst the quitters (Anthenelli, 2004). This may not be surprising since CB1 receptor antagonists were initially developed to control appetite and rimonabant (Acomplia™) is currently marketed mainly for this purpose.
Endocannobinoids are known to stimulate appetite and ingestive behaviours (see review by Kirkham, 2005). It is thought that CB1 receptors located in the nucleus accumbens and the hypothalamic nuclei mediate these hyperphagic actions of these substances. Blockade of CB1 receptors by rimonabant is known to attenuate stimulated release of extracellular dopamine exerted by various drug reinforcers, and this may be the common factor which underlies the potential of CB1 antagonists as ‘anti-craving’ agents (Cohen et al., 2005a).
The majority of studies examining the role of CB1 receptors in animal models of nicotine dependence have examined rimonabant. This antagonist has generated consistent findings from various rodent models such as the conditioned place preference (Le Foll and Goldberg, 2004) and cue-induced reinstatement models of nicotine-seeking behaviour (Cohen et al., 2005b). Other selective CB1 antagonists have been synthesised and studies are emerging which compare the efficacy of these analogues in various behavioural models. AM251 is a novel CB1 antagonist structurally related to rimonabant and shares similar potency and affinity for CB1 receptors (Gatley et al., 1996, Gatley et al., 1997). Although this compound has been shown to attenuate cocaine-seeking behaviour in rats (Xi et al., 2006), it has so far not been examined for its effects in behavioural models of nicotine dependence.
The present study aims to evaluate the effects of AM251 on nicotine self-administration behaviour and to compare these effects for specificity against responses maintained by food reinforcement. To better understand the nature of any alterations, each dose of AM251 is tested repeatedly over three successive sessions; the number of sessions necessary to observe extinction by saline substitution. The same doses of AM251 are further examined in a model of nicotine-seeking behaviour based upon reinstatement of extinguished responses produced by representation of nicotine and associated cues (Shoaib, 2006).
Section snippets
Animals
Male hooded Lister rats (Harlan, Bicester, UK) initially weighing 200–250 g were housed individually in a room maintained at 20–22 °C with a regular light–dark cycle (light from 8 a.m. to 8 p.m.). Once surgically prepared with an intravenous catheter, rats received their daily diet (20–24 g) approximately 1–2 h following the end of the self-administration session. For experiments involving food reinforcement, access to food was restricted to maintain body weights at 85% of those under free-feeding
Results
The majority of rats trained to self-administer nicotine acquired the task by the 18th session (data not shown). Once the stability criterion was met, extinction tests were conducted before tests with graded doses of AM251. Acquisition to lever-press for food pellets was relatively faster with all rats meeting the stability criterion by the 15th training session (data not shown).
Discussion
As shown previously with rimonabant, the CB1 receptor antagonist AM251 was found to reduce nicotine self-administration behaviour and reinstatement of nicotine-seeking behaviour in rats. The effect was prominent following a 1 mg/kg dose of AM251, which reduced nicotine-taking behaviour without significantly modifying the responses for food. In the larger doses, suppression of food-reinforced behaviour was observed but to a lesser extent compared to effects on nicotine-taking behaviour. These
Acknowledgements
I wish to thank the Medical Research Council and University of Newcastle for funding this research. Also, I thank Mr Sajid Shafait for assistance in training some of the rats and Professor Ian Stolerman for his encouragement and advice in facilitating this research.
References (33)
- et al.
Importance of nonpharmacological factors in nicotine self-administration
Physiology and Behavior
(2002) - et al.
Cannabinoid (CB)1 receptor antagonist, AM 251, causes a sustained reduction of daily food intake in the rat
Physiology and Behavior
(2004) - et al.
CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacology
Biochemistry and Behavior
(2005) - et al.
Suppression of conditioned nicotine and sucrose seeking by the cannabinoid-1 receptor antagonist SR141716A
Behavioural Brain Research
(2005) - et al.
123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors
European Journal of Pharmacology
(1996) - et al.
Current pharmacological treatments for nicotine dependence
Trends in Pharmacological Sciences
(2004) - et al.
Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats
European Journal of Pharmacology
(2006) The endocannabinoid system as a therapeutic target for smoking cessation
Meeting of the Society for Research on Nicotine and Tobacco
(2004)- et al.
Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors
Psychopharmacology
(1997) - et al.
Glutamate-dopamine interactions in the ventral striatum: role in locomotor activity and responding with conditioned reinforcement
Psychopharmacology
(1994)
Complex interactions between nicotine and nonpharmacological stimuli reveal multiple roles for nicotine in reinforcement
Psychopharmacology
Nicotine reinstatement of nicotine self-administration after long-term extinction
Psychopharmacology
SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats
Behavioural Pharmacology
Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716)
Neuropsychopharmacology
Appetite suppression and weight loss after the cannabinoid antagonist SR141716
Life Sciences
Cannabinoid CB1 receptors control conditioned drug seeking
Trends in Pharmacological Sciences
Cited by (83)
Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models
2020, NeuropharmacologyPreclinical and clinical research on the discriminative stimulus effects of nicotine
2020, NeuropharmacologyCitation Excerpt :For example, D3 receptor antagonists do not affect the DS effects of nicotine in rats (LeFoll et al., 2005) while they decrease nicotine reward (LeFoll et al., 2005). Similarly, antagonism of CB1 receptors has little effect against the DS effects of nicotine (Zaniewska et al., 2006) while compounds such as rimonabant and AM251 potently attenuate both nicotine-seeking (Cohen et al., 2005; Shoaib, 2008) and nicotine-taking behaviours (Shoaib, 2008). There is evidence to suggest that mild stimulants such as caffeine may produce similar changes on stimulus properties of nicotine (Gasior et al., 1999, 2002).
Nicotine Reward and Abstinence: Role of the CB1 Receptors
2019, Neuroscience of Nicotine: Mechanisms and TreatmentCannabinoids and the Addictive Effects of Nicotine
2017, Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis, and TreatmentThe Cannabinoid System in Nicotine Dependence and Withdrawal
2017, Negative Affective States and Cognitive Impairments in Nicotine Dependence